

I. AMENDMENTS

In the claims:

1-20 (Cancelled)

21. (Currently amended) A method of delivering rAAV recombinant adeno-associated virus virions to the brain of a subject suffering from a central nervous system (CNS) disorder, comprising:

(a) providing a pharmaceutical composition comprising rAAV recombinant adeno-associated virus virions, said rAAV recombinant adeno-associated virus virions encoding a therapeutic protein; and

(b) administering said composition to the brain of the subject such that widespread distribution of said rAAV recombinant adeno-associated virus virions is achieved and the therapeutic protein is expressed at levels that provide a therapeutic effect in said subject.

22. (Currently amended) The method of claim 21, wherein said rAAV is recombinant adeno-associated virus virions are administered using convection enhanced delivery.

23. (Previously added) The method of claim 22, wherein said convection enhanced delivery is performed using an infusion pump.

24. (Previously added) The method of claim 22, wherein said convection enhanced delivery is performed using an osmotic pump.

25. (Currently amended) The method of claim 21, wherein said rAAV is recombinant adeno-associated virus virions are administered to the striatum.